BioCryst Pharma (BCRX) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.24 -3.85%
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.6 million versus the consensus estimate of $6.34 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q1 EPS by 2c; Offers Guidance
- Melco Resorts & Entertainment (MLCO) Misses Q3 EPS by 9c
- Advantage Solutions Inc. (ADV) Misses Q3 EPS by 262c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
